Dilafor, a portfolio company of Karolinska Development, has attracted investors led by its manufacturing partner Opocrin to take its overall funding to more than $8.3m.
Dilafor, a Sweden-based obstetrical drug developer backed by Karolinska Development, the investment arm of Karolinska Institute, closed an Skr23.3m ($2.4m) funding round on Tuesday led by pharmaceuticals manufacturer Opocrin.
Karolinska Development’s shareholding is expected to rise in value with the transaction, resulting in a positive earnings impact of approximately $1.8m.
Founded in 2003, Dilafor is working on drugs for women undergoing maternal labour which aim to stimulate a hormone – oxytocin – responsible for a number of biological…
